BGLC

BioNexus Gene Lab Corp Common stock
NASDAQBASIC MATERIALSSPECIALTY CHEMICALS

Key Statistics

Market Cap
$4.62M
P/E Ratio
EPS
$-1.35
Beta
2.21
52W High
$8.98
52W Low
$1.07
50-Day MA
$2.15
200-Day MA
$3.32
Dividend Yield
Profit Margin
-54.70%
Forward P/E
PEG Ratio

About BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp. The company is headquartered in Kuala Lumpur, Malaysia.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$5.31M
Gross Profit (TTM)740,930
EBITDA$-2.96M
Operating Margin-2466.00%
Return on Equity-36.60%
Return on Assets-20.80%
Revenue/Share (TTM)$2.64
Book Value$3.35
Price-to-Book0.61
Price-to-Sales (TTM)0.87
EV/Revenue0.218
EV/EBITDA629.53
Quarterly Earnings Growth (YoY)-95.00%
Quarterly Revenue Growth (YoY)-98.90%
Shares Outstanding$2.42M
Float$1.76M
% Insiders35.59%
% Institutions0.01%

Historical Volatility

HV 10-Day
91.21%
HV 20-Day
104.56%
HV 30-Day
93.16%
HV 60-Day
69.64%
HV Rank

Volatility is currently contracting

Latest News

BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development

KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms, today highlighted its participation in the 2026 China–Malaysia Economic Cooperation Outlook Forum, held on May 21, 2026 at the Mandarin Oriental Hotel in Kuala Lumpur. The forum, held under the theme “Advancing Biotechnology and Healthcare Collaboration towards a China–Malaysia Community with a Shared Future,” brought together government representatives, industry leaders, investors, healthcare professionals, and experts from Malaysia and China to discuss strategic cooperation across biotechnology, healthcare, pharmaceutical development, infrastructure, and related sectors.

GlobeNewsWire5/29/2026Neutral

More BASIC MATERIALS Stocks

Data last updated: 7/9/2026